# Treatment Options for Protease Inhibitor-exposed Children

> **NCT01146873** · PHASE3 · COMPLETED · sponsor: **Columbia University** · enrollment: 300 (actual)

## Conditions studied

- HIV/AIDS
- HIV Infections

## Interventions

- **DRUG:** Efavirenz (EFV)
- **DRUG:** Lopinavir/ritonavir (LPV/r)
- **DRUG:** Stavudine (D4T)
- **DRUG:** Abacavir (ABC)

## Key facts

- **NCT ID:** NCT01146873
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2017-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01146873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01146873, "Treatment Options for Protease Inhibitor-exposed Children". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT01146873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*